There is a classification of BC defined by biomarkers by immunohistochemistry as estrogen receptor (ER), progesterone receptor (PR), receptor 2 of human epidermal growth factor (HER2), and Ki67 have been very useful to define molecular profiles,3, 4 which represent a guide for the diagnosis and treatment of patients.4 The molecular subtypes are classified in Luminal A, Luminal B, HER2, and triple negative (TN).5, 6 BC is a multifactorial disease in which pathogenesis merges several factors like environmental, genetic, and immunologic, where the proinflammatory cytokines highlight.7, 8, 9. This evidence concerns the gene ERBB2 and breast cancer.